-Newsclick.in The recent agreements between Medicine Patent Pool and Big Pharma are being projected as benevolent gestures from pharma companies in sharing their patented technologies with other countries. The fact is it is working towards cementing its monopoly power further. The development of anti-viral oral pills to combat COVID-19 will, hopefully, make the fight against the pandemic more promising. While Merck has developed the anti-viral pill Molnupiravir, Pfizer has come up with...

-Down to Earth Why did we grant Pfizer's claim on a pneumonia vaccine which has been rejected elsewhere? In august, the medical and public health fraternity was stunned when India’s Patent Office granted US pharma giant Pfizer’s claim on its vaccine against pneumonia, the pneumococcal conjugate vaccine (PCV), marketed as Prevnar13. For a country that has stricter patentability criteria than most others, India’s decision was baffling because Pfizer’s patent has been rejected...

-The Times of India NEW DELHI: New medicines for treatment of diabetes, hypertension and pneumonia are set to be cheaper from Diwali. Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has capped prices of as many as 18 new brands of essential medicines, most of which are expected to be launched in the market within a fortnight. The regulator has brought these medicines under price regulation using paragraph 5 of the Drugs...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...

-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...